Research Analysts Set Expectations for Myomo Q1 Earnings

Myomo, Inc. (NYSEAMERICAN:MYO - Free Report) - Analysts at HC Wainwright lifted their Q1 2025 earnings per share estimates for shares of Myomo in a research note issued to investors on Wednesday, March 12th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.09) per share for the quarter, up from their prior estimate of ($0.11). HC Wainwright currently has a "Buy" rating and a $9.50 target price on the stock. The consensus estimate for Myomo's current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo's Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.13) EPS and FY2027 earnings at $0.20 EPS.

A number of other research firms have also commented on MYO. Alliance Global Partners reaffirmed a "buy" rating on shares of Myomo in a research report on Tuesday, March 11th. Craig Hallum upped their target price on Myomo from $9.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, March 11th. Finally, Ascendiant Capital Markets upped their target price on Myomo from $9.00 to $11.00 and gave the stock a "buy" rating in a report on Monday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Myomo presently has an average rating of "Buy" and a consensus target price of $9.75.

Myomo Trading Down 1.5 %

Shares of NYSEAMERICAN MYO traded down $0.08 during midday trading on Monday, reaching $5.40. The company had a trading volume of 215,922 shares, compared to its average volume of 336,095. The firm has a market cap of $163.23 million, a PE ratio of -23.46 and a beta of 1.68. Myomo has a one year low of $2.51 and a one year high of $7.17.

Remove Ads

Hedge Funds Weigh In On Myomo

Several large investors have recently made changes to their positions in the business. Barclays PLC bought a new stake in Myomo during the third quarter worth approximately $36,000. BNP Paribas Financial Markets bought a new stake in Myomo during the fourth quarter worth approximately $64,000. Jane Street Group LLC bought a new stake in Myomo during the third quarter worth approximately $65,000. Walleye Capital LLC bought a new stake in Myomo during the fourth quarter worth approximately $66,000. Finally, Squarepoint Ops LLC bought a new stake in Myomo during the fourth quarter worth approximately $74,000. 44.99% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Micah Mitchell sold 48,000 shares of the business's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $5.16, for a total value of $247,680.00. Following the transaction, the insider now directly owns 140,572 shares in the company, valued at $725,351.52. The trade was a 25.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Thomas F. Kirk acquired 7,400 shares of the stock in a transaction dated Thursday, March 13th. The stock was acquired at an average price of $5.00 per share, for a total transaction of $37,000.00. Following the completion of the transaction, the director now directly owns 255,933 shares of the company's stock, valued at approximately $1,279,665. This represents a 2.98 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 4.54% of the company's stock.

About Myomo

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.